Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants legally competent to sign and give informed consent.~2. Males and females ages 18 years and older (inclusive) at the time of consent.~3. Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as determined by the Investigator. Stable disease for the past 4 weeks.~4. Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous areas.~5. An Investigator Global Assessment (IGA) of disease severity of at least Moderate ('3') at Baseline.~6. Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.~7. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).~8. Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.~9. Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.~10. Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.~Exclusion Criteria:~1. Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study according to Excluded Medications and Treatments.~2. Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.~3. Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study.~4. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.~5. Subjects with PHQ-8 ≥10 at Screening or Baseline visits.~6. Previous treatment with ARQ-151 and ARQ-154.~7. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE-4 inhibitors (apremilast) within the past 4 weeks.~8. Known allergies to excipients in ARQ-154 foam.~9. Known or suspected: severe renal insufficiency or moderate to severe hepatic disorders; hypersensitivity to component(s) of the investigational products; or history of severe depression, suicidal ideation, or Baseline/Screening C-SSRS indicative of suicidal ideation, whether lifetime or recent/current.~10. Subjects with a history of a major surgery within 8 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.~11. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.~12. Subjects unable to apply product to the scalp due to physical limitations.~13. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~14. A clinically relevant history of abuse of alcohol or other drugs, at the discretion of the Investigator.~15. Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.~16. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects.~17. Any condition that in the Investigator's assessment would preclude the subject from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast Foam 0.3% (Type: ACTIVE_COMPARATOR): Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).